Share-based Payment Arrangement, Expense of OCULAR THERAPEUTIX, INC from 31 Dec 2012 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
OCULAR THERAPEUTIX, INC quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2012 to 30 Sep 2025.
  • OCULAR THERAPEUTIX, INC Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $11,691,000, a 76% increase year-over-year.
  • OCULAR THERAPEUTIX, INC Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $39,022,000, a 29% increase year-over-year.
  • OCULAR THERAPEUTIX, INC annual Share-based Payment Arrangement, Expense for 2024 was $33,109,000, a 86% increase from 2023.
  • OCULAR THERAPEUTIX, INC annual Share-based Payment Arrangement, Expense for 2023 was $17,825,000, a 5.1% increase from 2022.
  • OCULAR THERAPEUTIX, INC annual Share-based Payment Arrangement, Expense for 2022 was $16,964,000, a 13% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

OCULAR THERAPEUTIX, INC Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $39,022,000 $11,691,000 +$5,050,000 +76% 01 Jul 2025 30 Sep 2025 10-Q 04 Nov 2025 2025 Q3
Q2 2025 $33,972,000 $9,678,000 -$1,615,000 -14% 01 Apr 2025 30 Jun 2025 10-Q 05 Aug 2025 2025 Q2
Q1 2025 $35,587,000 $10,456,000 +$2,478,000 +31% 01 Jan 2025 31 Mar 2025 10-Q 05 May 2025 2025 Q1
Q4 2024 $33,109,000 $7,197,000 +$2,869,000 +66% 01 Oct 2024 31 Dec 2024 10-K 03 Mar 2025 2024 FY
Q3 2024 $30,240,000 $6,641,000 +$2,129,000 +47% 01 Jul 2024 30 Sep 2024 10-Q 04 Nov 2025 2025 Q3
Q2 2024 $28,111,000 $11,293,000 +$6,880,000 +156% 01 Apr 2024 30 Jun 2024 10-Q 05 Aug 2025 2025 Q2
Q1 2024 $21,231,000 $7,978,000 +$3,406,000 +74% 01 Jan 2024 31 Mar 2024 10-Q 05 May 2025 2025 Q1
Q4 2023 $17,825,000 $4,328,000 +$94,000 +2.2% 01 Oct 2023 31 Dec 2023 10-K 03 Mar 2025 2024 FY
Q3 2023 $17,731,000 $4,512,000 +$272,000 +6.4% 01 Jul 2023 30 Sep 2023 10-Q 14 Nov 2024 2024 Q3
Q2 2023 $17,459,000 $4,413,000 +$132,000 +3.1% 01 Apr 2023 30 Jun 2023 10-Q 07 Aug 2024 2024 Q2
Q1 2023 $17,327,000 $4,572,000 +$363,000 +8.6% 01 Jan 2023 31 Mar 2023 10-Q 07 May 2024 2024 Q1
Q4 2022 $16,964,000 $4,234,000 +$392,000 +10% 01 Oct 2022 31 Dec 2022 10-K 03 Mar 2025 2024 FY
Q3 2022 $16,572,000 $4,240,000 +$482,000 +13% 01 Jul 2022 30 Sep 2022 10-Q 07 Nov 2023 2023 Q3
Q2 2022 $16,090,000 $4,281,000 -$11,000 -0.26% 01 Apr 2022 30 Jun 2022 10-Q 07 Aug 2023 2023 Q2
Q1 2022 $16,101,000 $4,209,000 +$1,123,000 +36% 01 Jan 2022 31 Mar 2022 10-Q 08 May 2023 2023 Q1
Q4 2021 $14,978,000 $3,842,000 +$1,738,000 +83% 01 Oct 2021 31 Dec 2021 10-K 11 Mar 2024 2023 FY
Q3 2021 $13,240,000 $3,758,000 +$1,822,000 +94% 01 Jul 2021 30 Sep 2021 10-Q 07 Nov 2022 2022 Q3
Q2 2021 $11,418,000 $4,292,000 +$2,466,000 +135% 01 Apr 2021 30 Jun 2021 10-Q 08 Aug 2022 2022 Q2
Q1 2021 $8,952,000 $3,086,000 +$1,421,000 +85% 01 Jan 2021 31 Mar 2021 10-Q 09 May 2022 2022 Q1
Q4 2020 $7,531,000 $2,104,000 +$151,000 +7.7% 01 Oct 2020 31 Dec 2020 10-K 06 Mar 2023 2022 FY
Q3 2020 $7,380,000 $1,936,000 -$1,233,000 -39% 01 Jul 2020 30 Sep 2020 10-Q 08 Nov 2021 2021 Q3
Q2 2020 $8,613,000 $1,826,000 +$131,000 +7.7% 01 Apr 2020 30 Jun 2020 10-Q 09 Aug 2021 2021 Q2
Q1 2020 $8,482,000 $1,665,000 -$277,000 -14% 01 Jan 2020 31 Mar 2020 10-Q 05 May 2021 2021 Q1
Q4 2019 $8,759,000 $1,953,000 01 Oct 2019 31 Dec 2019 10-K 28 Feb 2022 2021 FY
Q3 2019 $3,169,000 +$1,296,000 +69% 01 Jul 2019 30 Sep 2019 10-Q 05 Nov 2020 2020 Q3
Q2 2019 $1,695,000 -$135,000 -7.4% 01 Apr 2019 30 Jun 2019 10-Q 07 Aug 2020 2020 Q2
Q1 2019 $1,942,000 +$111,000 +6.1% 01 Jan 2019 31 Mar 2019 10-Q 08 May 2020 2020 Q1
Q3 2018 $1,873,000 +$122,000 +7% 01 Jul 2018 30 Sep 2018 10-Q 12 Nov 2019 2019 Q3
Q2 2018 $1,830,000 +$73,000 +4.2% 01 Apr 2018 30 Jun 2018 10-Q 07 Aug 2019 2019 Q2
Q1 2018 $1,831,000 +$126,000 +7.4% 01 Jan 2018 31 Mar 2018 10-Q 10 May 2019 2019 Q1
Q3 2017 $1,751,000 +$382,000 +28% 01 Jul 2017 30 Sep 2017 10-Q 07 Nov 2018 2018 Q3
Q2 2017 $1,757,000 +$242,000 +16% 01 Apr 2017 30 Jun 2017 10-Q 07 Aug 2018 2018 Q2
Q1 2017 $1,705,000 01 Jan 2017 31 Mar 2017 10-Q 08 May 2018 2018 Q1
Q3 2016 $1,369,000 01 Jul 2016 30 Sep 2016 10-Q 07 Nov 2017 2017 Q3
Q2 2016 $1,515,000 01 Apr 2016 30 Jun 2016 10-Q 08 Aug 2017 2017 Q2
Q3 2014 $607,000 +$486,000 +402% 01 Jul 2014 30 Sep 2014 10-Q 12 Nov 2014 2014 Q3
Q2 2014 $557,000 +$436,000 +360% 01 Apr 2014 30 Jun 2014 10-Q 29 Aug 2014 2014 Q2
Q3 2013 $121,000 01 Jul 2013 30 Sep 2013 10-Q 12 Nov 2014 2014 Q3
Q2 2013 $121,000 01 Apr 2013 30 Jun 2013 10-Q 29 Aug 2014 2014 Q2

OCULAR THERAPEUTIX, INC Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $33,109,000 +$15,284,000 +86% 01 Jan 2024 31 Dec 2024 10-K 03 Mar 2025 2024 FY
2023 $17,825,000 +$861,000 +5.1% 01 Jan 2023 31 Dec 2023 10-K 03 Mar 2025 2024 FY
2022 $16,964,000 +$1,986,000 +13% 01 Jan 2022 31 Dec 2022 10-K 03 Mar 2025 2024 FY
2021 $14,978,000 +$7,447,000 +99% 01 Jan 2021 31 Dec 2021 10-K 11 Mar 2024 2023 FY
2020 $7,531,000 -$1,228,000 -14% 01 Jan 2020 31 Dec 2020 10-K 06 Mar 2023 2022 FY
2019 $8,759,000 01 Jan 2019 31 Dec 2019 10-K 28 Feb 2022 2021 FY
2014 $2,644,000 +$2,168,000 +455% 01 Jan 2014 31 Dec 2014 10-K 20 Mar 2015 2014 FY
2013 $476,000 +$233,000 +96% 01 Jan 2013 31 Dec 2013 10-K 20 Mar 2015 2014 FY
2012 $243,000 01 Jan 2012 31 Dec 2012 10-K 20 Mar 2015 2014 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.